153 related articles for article (PubMed ID: 30616626)
1. Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone.
de Anda-Jáuregui G; Guo K; McGregor BA; Feldman EL; Hur J
BMC Syst Biol; 2019 Jan; 13(1):1. PubMed ID: 30616626
[TBL] [Abstract][Full Text] [Related]
2. Correction to: Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone.
de Anda-Jáuregui G; Guo K; McGregor BA; Feldman EL; Hur J
BMC Syst Biol; 2019 Mar; 13(1):31. PubMed ID: 30866938
[No Abstract] [Full Text] [Related]
3. The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.
Santos DFS; Donahue RR; Laird DE; Oliveira MCG; Taylor BK
Neuropharmacology; 2022 Mar; 205():108907. PubMed ID: 34856203
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.
Elkholy SE; Elaidy SM; El-Sherbeeny NA; Toraih EA; El-Gawly HW
Life Sci; 2020 Jun; 250():117557. PubMed ID: 32184124
[TBL] [Abstract][Full Text] [Related]
5. Molecular network-based analysis of guizhi-shaoyao-zhimu decoction, a TCM herbal formula, for treatment of diabetic peripheral neuropathy.
Zhao N; Li J; Li L; Niu XY; Jiang M; He XJ; Bian ZX; Zhang G; Lu AP
Acta Pharmacol Sin; 2015 Jun; 36(6):716-23. PubMed ID: 25948477
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-1/Tie2 signaling pathway contributes to the therapeutic effect of thymosin β4 on diabetic peripheral neuropathy.
Wang L; Chopp M; Szalad A; Lu X; Lu M; Zhang T; Zhang ZG
Neurosci Res; 2019 Oct; 147():1-8. PubMed ID: 30326249
[TBL] [Abstract][Full Text] [Related]
7. Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks.
Martin F; Thomson TM; Sewer A; Drubin DA; Mathis C; Weisensee D; Pratt D; Hoeng J; Peitsch MC
BMC Syst Biol; 2012 May; 6():54. PubMed ID: 22651900
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story.
Hinder LM; Murdock BJ; Park M; Bender DE; O'Brien PD; Rumora AE; Hur J; Feldman EL
Exp Neurol; 2018 Jul; 305():33-43. PubMed ID: 29550371
[TBL] [Abstract][Full Text] [Related]
9. The Role of Oxidative Stress in Diabetic Neuropathy: Generation of Free Radical Species in the Glycation Reaction and Gene Polymorphisms Encoding Antioxidant Enzymes to Genetic Susceptibility to Diabetic Neuropathy in Population of Type I Diabetic Patients.
Babizhayev MA; Strokov IA; Nosikov VV; Savel'yeva EL; Sitnikov VF; Yegorov YE; Lankin VZ
Cell Biochem Biophys; 2015 Apr; 71(3):1425-43. PubMed ID: 25427889
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes.
Pande M; Hur J; Hong Y; Backus C; Hayes JM; Oh SS; Kretzler M; Feldman EL
Diabetes; 2011 Jul; 60(7):1981-9. PubMed ID: 21617178
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone attenuates ischaemic stroke aggravation by blocking PPARγ reduction and inhibiting chronic inflammation in diabetic mice.
Guo Y; Zuo W; Yin L; Gu T; Wang S; Fang Z; Wang B; Dong H; Hou W; Zuo Z; Deng J
Eur J Neurosci; 2022 Sep; 56(6):4948-4961. PubMed ID: 35945686
[TBL] [Abstract][Full Text] [Related]
12. miR-146a mediates thymosin β4 induced neurovascular remodeling of diabetic peripheral neuropathy in type-II diabetic mice.
Wang L; Chopp M; Lu X; Szalad A; Jia L; Liu XS; Wu KH; Lu M; Zhang ZG
Brain Res; 2019 Mar; 1707():198-207. PubMed ID: 30500399
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice.
Patel O; Muller CJF; Joubert E; Rosenkranz B; Louw J; Awortwe C
PLoS One; 2021; 16(5):e0251069. PubMed ID: 33983968
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice.
Wang L; Chopp M; Szalad A; Liu Z; Bolz M; Alvarez FM; Lu M; Zhang L; Cui Y; Zhang RL; Zhang ZG
Neuroscience; 2011 Oct; 193():399-410. PubMed ID: 21820491
[TBL] [Abstract][Full Text] [Related]
15. Alternative pathway approach for automating analysis and validation of cell perturbation networks and design of perturbation experiments.
Gong Y; Zhang Z
Ann N Y Acad Sci; 2007 Dec; 1115():267-85. PubMed ID: 17925355
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions.
Mehta K; Behl T; Kumar A; Uddin MS; Zengin G; Arora S
Curr Protein Pept Sci; 2021; 22(1):4-18. PubMed ID: 33292149
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of potential gene crosstalk between non-alcoholic fatty liver disease and diabetic nephropathy.
Yan Q; Zhao Z; Liu D; Li J; Pan S; Duan J; Dong J; Liu Z
Front Endocrinol (Lausanne); 2022; 13():1032814. PubMed ID: 36387855
[TBL] [Abstract][Full Text] [Related]
18. Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes.
Hinder LM; Vivekanandan-Giri A; McLean LL; Pennathur S; Feldman EL
J Endocrinol; 2013 Jan; 216(1):1-11. PubMed ID: 23086140
[TBL] [Abstract][Full Text] [Related]
19. Boolean factor graph model for biological systems: the yeast cell-cycle network.
Kotiang S; Eslami A
BMC Bioinformatics; 2021 Sep; 22(1):442. PubMed ID: 34535069
[TBL] [Abstract][Full Text] [Related]
20. Diabetic peripheral neuropathy: current perspective and future directions.
Singh R; Kishore L; Kaur N
Pharmacol Res; 2014 Feb; 80():21-35. PubMed ID: 24373831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
